Cannabinoids as Inhibitor of Tumour Growth and Invasiveness in Small Intestine Neuroendocrine Cancer Abstract #1560

Introduction: Tumour cell invasion and proliferation is a key factor for the prognosis and progression of cancer. A recent study revealed that cannabinoids can inhibit tumour invasion and proliferation in breast cancer through the down-regulation of ID-1, an inhibitor of helix-turn-helix transcription factors.
Aim(s): ID1 is highly expressed in the small intestine neuroendocrine tumour cell line P-STS. We therefore hypothesize that cannabinoids can also inhibit proliferation and invasion of P-STS via the down-regulation of ID-1.
Materials and methods: P-STS cells were treated with the CB-receptor agonist WIN-55,212. Subsequently, the ID1 expression was observed and proliferation, viability, apoptosis and mitosis were assessed. The tumour cells were xenografted onto a chicken chorioallantoic membrane (CAM) and the tissue was further stained immunohistochemically for Ki67 and a TUNEL-Assay was performed. Angiogenesis was assessed with CAM-Assays.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Ruben Errampalli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)
Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Sonja Levy
Keywords: SI-NET, Nomogram, Survival
#2783 Use of Plasma Proteins to Predict Progressive Disease in Patients with Small Intestinal Neuroendocrine Tumours
Introduction: Prediction of progression in small intestinal neuroendocrine tumors (SI-NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD PhD Roger Belusa
#1115 Cancer Stem Cells in Small Intestine Neuroendocrine Cell Line P-STS: Isolation and Molecular Characterisation
Introduction: Cancer stem cells (CSCs) represent a small subpopulation of tumour cells responsible for invasive tumour growth. Even though the presence of CSCs in neuroendocrine tumours is documented, their role in neuroendocrine tumourigenesis and metastasis is not defined as yet.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Florian Kleinegger
#2982 Comprehensive Molecular Analysis Identifies Driver Mutations in Metastases of Sporadic Well-Differentiated Neuroendocrine Tumours of the Small Intestine
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) represent a heterogenous group of tumours. The molecular mechanisms which contribute to progression of SI-NETs are poorly elucidated. They are considered to be molecularly distinct from neuroendocrine carcinomas (NECs), which share oncogenic pathways with adenocarcinomas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Drs Kris Samsom
#2706 A New Possibility in SI-NET Surgery by Using a New β- Probe and 90Y-DOTATOC: A Pilot Study
Introduction: In neuroendocrine tumor (NET), complete surgery could better the prognosis of this disease: radioguided surgery (RGS) with beta-radioisotopes, as 90Y, is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with low radiation exposition for surgeons.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Chiara Maria Grana